ArticleDrug design, development and therapy2024

Neurophysiological Characteristics in Type II and Type III 5q Spinal Muscular Atrophy Patients: Impact of Nusinersen Treatment.

Dan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.